Government officials in Guinea-Bissau have formally rejected a clinical trial that would be run by Danish researchers and funded by the US to look for alleged nonspecific harms from the newborn dose of the hepatitis B vaccine. The vaccine dose is currently recommended globally for all newborns and has been used safely and effectively for decades.
In an email to Ars Technica, one of the trial's lead researchers, Christine Stabell Benn of Bandim Health Project and the University of Southern Denmark, said that Guinea-Bissau's Council of Ministers "formally reaffirmed its non-acceptance of the study on 16 October."
The revelation that the study was formally rejected last week comes after news on Monday that judicial police in Guinea-Bissau raided Bandim Health's offices and seized vaccines. Stabell Benn highlighted that the police search came after the trial was rejected.